Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony‑stimulating factor(PEG‑rhG‑CSF)for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer  

作　　者：Tingting Yu Yiwei Zhang Jiawen Li Zhuo Li Rui Tong 

机构地区：[1]Affiliated Cancer Hospital of Dalian University of Technology,Liaoning Cancer Hospital,Dalian,China

出　　处：《Holistic Integrative Oncology》2024年第1期424-435,共12页整合肿瘤学(英文)

基　　金：supported by The Beijing Heathco Clinical Oncology Research Foundation(Y-SY201901-0198).

摘　　要：Objective The efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)in the prevention of leukopenia/neutropenia during concurrent chemoradiotherapy for cervical cancer were investigated.Methods The patients who received concurrent radiotherapy and chemotherapy for cervical cancer from June 2020 to January 2023 were selected to evaluate the difference in efficacy,adverse reactions,and treatment cost of PEG-rhG-CSF in the prevention of leukopenia/neutropenia between the test group and the control group.Results The minimum value of leukopenia/neutropenia in the test group was significantly higher than that in the control group(P<0.05).The incidence of grade≥3 leukopenia/neutropenia was significantly lower than that of the control group(P<0.05).The number of interrupted days of radiotherapy was less than that of the control group(P<0.05).PEG-rhG-CSF of different prophylactic doses(100μg/kg dose or 50μg/kg dose)had similar prophylactic effects in the test group,OR=1.192(0.761,1.868),P=0.443.Conclusion Prophylactic application of PEG-rhG-CSF could reduce the incidence of leukopenia/neutropenia in cervi-cal cancer during concurrent chemoradiotherapy.There was no significant difference in efficacy and safety with pro-phylactic use of drug at doses of 100μg/kg and 50μg/kg.

关 键 词：Cervical cancer CHEMORADIOTHERAPY NEUTROPENIA PEG-rhG-CSF 

分 类 号：R73[医药卫生—肿瘤]